Living Cell Technologies Ltd. (AU:1AI) has released an update.
Algorae Pharmaceuticals Ltd. announces the successful launch of its AI-driven platform, AlgoraeOS, reaching a significant milestone with a Technology Readiness Level of 3+. The platform, which predicts fixed-dose combination drug targets, has demonstrated high accuracy in initial tests and is set for further development in collaboration with industry experts. This breakthrough offers potential for more effective drug development, promising commercial opportunities for investors and improved treatments for patients.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.
